What is Savara's cash & equivalents?

Savara (SVRA) reported cash & equivalents of $38.79M in Q1 2026.

How has Savara's cash & equivalents changed year-over-year?

Savara's cash & equivalents increased by 98.4% year-over-year, from $19.56M to $38.79M.

What is the long-term trend for Savara's cash & equivalents?

Over 5 years (2020 to 2025), Savara's cash & equivalents has grown at a 7.7% compound annual growth rate (CAGR), from $22.88M to $33.18M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Savara SVRA Cash & Equivalents

Cash & Equivalents at other companies

XER

Xeris Biopharma Holdings, Inc.XERS

$111.75M+91.2%

Zevra Therapeutics, Inc.ZVRA

$95.6M+156%

Innoviva, Inc.INVA

$603.09M+89.0%

Theravance BiopharmaTBPH

$288.1M+160%

ANI PharmaceuticalsANIP

$311.21M+108%

Eton Pharmaceuticals, Inc.ETON

$19.66M+12.9%

Other financials

Income statement

See full

Revenue-—

Operating income-$39.0M-37.1%

Net income-$37.3M-40.0%

EPS (diluted)-$0.15-25.0%

Balance sheet

See full

Total debt$30.1M+1.8%

Total equity$176.0M+19.1%

Total assets$221.6M+17.1%

Cash flow

See full

Operating cash flow-$33.0M-21.5%

CapEx$54.0K+1,700%

Free cash flow-$33.1M-21.7%

Valuation

See full

Market cap$1.19B+236%

Enterprise value$1.19B+224%

P/S4,648.7×—

Profitability

See full

Operating margin-19,183.3%—

Net margin-19,305.1%—

FCF margin-15,518.7%—

Returns & leverage

See full

Return on equity-80%+4.7pp

Debt / equity0.2×0.0×

Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Savara's cash & equivalents?: Savara (SVRA) reported cash & equivalents of $38.79M in Q1 2026.
How has Savara's cash & equivalents changed year-over-year?: Savara's cash & equivalents increased by 98.4% year-over-year, from $19.56M to $38.79M.
What is the long-term trend for Savara's cash & equivalents?: Over 5 years (2020 to 2025), Savara's cash & equivalents has grown at a 7.7% compound annual growth rate (CAGR), from $22.88M to $33.18M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.